Spots Global Cancer Trial Database for her2 positive
Every month we try and update this database with for her2 positive cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Dose Finding Study for Combination of Capecitabine, Lapatinib and Vinorelbine in Metastatic Breast Cancer | NCT01238029 | Metastatic Brea... HER2 Positive First or Second... Failure or Cont... | Lapatinib and C... | 18 Years - | Sponsor GmbH | |
| Targeted Next Generation Sequencing for the Efficacy of Trastuzumab Neoadjuvant Chemotherapy in Breast Cancer | NCT03728829 | Observational Prospective | Trastuzumab+TP | 18 Years - 70 Years | Hebei Medical University Fourth Hospital | |
| HKI-272 for HER2-Positive Breast Cancer and Brain Metastases | NCT01494662 | Breast Cancer | HKI-272 Surgical Resect... Capecitabine HKI-272 Ado-Trastuzumab... | 18 Years - | Dana-Farber Cancer Institute | |
| Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation | NCT04208178 | Advanced HER2+B... | Alpelisib Alpelisib match... Trastuzumab Pertuzumab | 18 Years - | Novartis | |
| Phase III to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast Cancer | NCT01875367 | Breast Cancer | Trastuzumab Inj... Trastuzumab Inj... Trastuzumab Inj... | 18 Years - | Spanish Breast Cancer Research Group | |
| A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04) | NCT02187744 | Early Breast Ca... | PF-05280014 Taxotere® Paraplatin® Trastuzumab-EU Taxotere® Paraplatin® | 18 Years - | Pfizer | |
| Dose Finding Study for Combination of Capecitabine, Lapatinib and Vinorelbine in Metastatic Breast Cancer | NCT01238029 | Metastatic Brea... HER2 Positive First or Second... Failure or Cont... | Lapatinib and C... | 18 Years - | Sponsor GmbH | |
| A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer | NCT02236000 | Breast Cancer | Neratinib T-DM1 | 18 Years - | NSABP Foundation Inc | |
| Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2 | NCT01996267 | Breast Cancer HER2 Positive | PTC+Pertuzumab FEC-T+Pertuzuma... | 18 Years - | The Netherlands Cancer Institute | |
| A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer | NCT02202746 | Breast Cancer Metastatic Brea... MBC HER2 Positive HER2 Estrogen Recept... ER Triple Negative | Lucitanib | 18 Years - | Clovis Oncology, Inc. | |
| Treatment Options in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer Patients | NCT01782651 | Neoplasms, Brea... | Lapatinib plus ... | 18 Years - | GlaxoSmithKline | |
| FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors | NCT03319459 | HER2 Positive G... Colorectal Canc... Head and Neck S... EGFR Positive S... Advanced Solid ... HER2-positive B... Hepatocellular ... Non Small Cell ... Renal Cell Carc... Pancreatic Canc... Melanoma | FATE-NK100 Cetuximab Trastuzumab | 18 Years - | Fate Therapeutics | |
| Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | NCT04464967 | Advanced Solid ... Metastatic Canc... HER2-positive B... HER2-positive G... HER-2 Protein O... Esophageal Canc... Ovarian Cancer Endometrium Can... Bladder Cancer Pancreatic Canc... Colorectal Canc... Non Small Cell ... EGF-R Positive ... Head and Neck S... Triple Negative... Cervical Cancer Sarcoma | SNK01 Trastuzumab Cetuximab | 18 Years - 75 Years | NKGen Biotech, Inc. | |
| A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. | NCT01783444 | Breast Cancer | Capecitabine Exemestane Everolimus | 18 Years - | Novartis | |
| Vaccination of Triple Negative Breast Cancer Patients | NCT02938442 | Triple Negative... Breast Neoplasm... | P10s-PADRE with... Doxorubicin + C... | 18 Years - | University of Arkansas | |
| Lapatinib and Temozolomide for the Treatment of Progressive Brain Disease in HER-2 Positive Breast Cancer | NCT00614978 | Metastatic Brea... Brain Metastase... HER2 Positive | lapatinib and t... | 18 Years - 70 Years | Jules Bordet Institute | |
| A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors | NCT02403271 | Non-Small Cell ... Breast Cancer Pancreatic Canc... | Ibrutinib Durvalumab | 18 Years - | Pharmacyclics LLC. | |
| PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer | NCT01973660 | Breast Cancer | Lapatinib Trastuzumab Endocrine Thera... Paclitaxel | 18 Years - | SOLTI Breast Cancer Research Group | |
| A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients | NCT03013504 | HER2 Positive B... | HD201 Herceptin Docetaxel Epirubicin Cyclophosphamid... | 18 Years - | Prestige Biopharma Limited | |
| Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib | NCT05252988 | Early-stage Bre... HER2 Positive B... Hormone Recepto... | Neratinib Loperamide Colesevelam | 18 Years - | Spanish Breast Cancer Research Group | |
| Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer | NCT03368729 | Metastatic Brea... HER2 Positive B... | Niraparib Trastuzumab | 18 Years - | University of Alabama at Birmingham | |
| Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 Therapies | NCT02238509 | Metastatic Brea... | Lapatinib Trastuzumab | 18 Years - | Consorzio Oncotech | |
| A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. | NCT01783444 | Breast Cancer | Capecitabine Exemestane Everolimus | 18 Years - | Novartis | |
| Vaccination of Triple Negative Breast Cancer Patients | NCT02938442 | Triple Negative... Breast Neoplasm... | P10s-PADRE with... Doxorubicin + C... | 18 Years - | University of Arkansas | |
| A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer | NCT03429101 | Breast Cancer | Poziotinib T-DM1 | 18 Years - 90 Years | Spectrum Pharmaceuticals, Inc | |
| Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research | NCT01016886 | Breast Cancer Heart Failure | perindopril OR ... | 18 Years - | AHS Cancer Control Alberta | |
| A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer | NCT01160211 | Neoplasms, Brea... | lapatinib trastuzumab Aromatase inhib... lapatinib | 18 Years - | Novartis | |
| Monalizumab and Trastuzumab In Metastatic HER2-pOSitive breAst Cancer: MIMOSA-trial | NCT04307329 | Breast Cancer | Monalizumab Trastuzumab | 18 Years - | The Netherlands Cancer Institute | |
| A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer | NCT02202746 | Breast Cancer Metastatic Brea... MBC HER2 Positive HER2 Estrogen Recept... ER Triple Negative | Lucitanib | 18 Years - | Clovis Oncology, Inc. | |
| Monalizumab and Trastuzumab In Metastatic HER2-pOSitive breAst Cancer: MIMOSA-trial | NCT04307329 | Breast Cancer | Monalizumab Trastuzumab | 18 Years - | The Netherlands Cancer Institute | |
| Phase III to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast Cancer | NCT01875367 | Breast Cancer | Trastuzumab Inj... Trastuzumab Inj... Trastuzumab Inj... | 18 Years - | Spanish Breast Cancer Research Group | |
| Oral Vinorelbine in Combination With Trastuzumab for Metastatic Breast Cancer | NCT01242449 | Breast Cancer | Trastuzumab Vinorelbine | 18 Years - | Vejle Hospital | |
| Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research | NCT01016886 | Breast Cancer Heart Failure | perindopril OR ... | 18 Years - | AHS Cancer Control Alberta | |
| A Study to Evaluate Vinorelbine Plus Capecitabine Combined With Trastuzumab for HER2 Positive Patients Following Neoadjuvant Chemotherapy | NCT04302441 | Breast Cancer | Vinorelbine Capecitabine | 18 Years - 70 Years | Fudan University | |
| Study of Neoadjuvant Myocet®, Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer | NCT01669239 | Breast Cancer | Liposomal Doxor... | 18 Years - 74 Years | SOLTI Breast Cancer Research Group | |
| Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2 | NCT01996267 | Breast Cancer HER2 Positive | PTC+Pertuzumab FEC-T+Pertuzuma... | 18 Years - | The Netherlands Cancer Institute | |
| Dose Escalation Followed by Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer | NCT00458237 | Breast Cancer | Everolimus Trastuzumab | 18 Years - | Dana-Farber Cancer Institute | |
| Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting | NCT00618657 | Breast Cancer HER2-negative B... HER2-positive B... Recurrent Breas... Stage IA Breast... Stage IB Breast... Stage II Breast... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... | Carboplatin paclitaxel albu... bevacizumab trastuzumab magnetic resona... therapeutic con... | 21 Years - 90 Years | University of California, Irvine | |
| Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer | NCT00263588 | Neoplasms, Brea... | lapatinib | 18 Years - | Novartis | |
| Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2 | NCT01996267 | Breast Cancer HER2 Positive | PTC+Pertuzumab FEC-T+Pertuzuma... | 18 Years - | The Netherlands Cancer Institute | |
| RWD Study in HER2+ mBC Patients in Third-Line Therapy | NCT04566458 | Breast Cancer S... | No intervention | 18 Years - | Exactis Innovation | |
| A Dose Escalation Study of Proton and Carbon Ion Irradiation for HER2 Positive and Triple Negative Breast Cancer | NCT05692661 | Triple Negative... HER2-positive B... | proton plus car... | 18 Years - 80 Years | Shanghai Proton and Heavy Ion Center | |
| Evaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic Therapy | NCT04928261 | Breast Cancer | Trastuzumab | 18 Years - | Ottawa Hospital Research Institute | |
| Trastuzumab and Vinorelbine in Advanced Breast Cancer | NCT01185509 | Breast Cancer Metastatic Brea... | trastuzumab vinorelbine | 18 Years - | Dana-Farber Cancer Institute | |
| Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast Cancer | NCT04152057 | Breast Cancer HER2 Positive Combination Che... | Pyrotinib Malea... Albumin Paclita... Trastuzumab | 18 Years - 70 Years | West China Hospital | |
| CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer | NCT01191697 | Esophageal Canc... Gastric Cancer | bevacizumab trastuzumab oxaliplatin capecitabine | 18 Years - | Dana-Farber Cancer Institute | |
| A Study to Look at the Combination of Chemotherapy, Trastuzumab and RAD001 in HER2 Positive Breast Cancer | NCT01163929 | Breast Cancer | paclitaxel | 18 Years - 65 Years | University of Kansas Medical Center | |
| A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,) | NCT05283837 | Metastatic Brea... | Pertuzumab (ZRC... Pertuzumab (Per... | 18 Years - 65 Years | Zydus Lifesciences Limited | |
| A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) | NCT05002127 | Gastric Cancer Gastroesophagea... Gastric Adenoca... | Evorpacept (ALX... Trastuzumab Ramucirumab Paclitaxel | 18 Years - | ALX Oncology Inc. | |
| Oral Vinorelbine in Combination With Trastuzumab for Metastatic Breast Cancer | NCT01242449 | Breast Cancer | Trastuzumab Vinorelbine | 18 Years - | Vejle Hospital | |
| Efficacy and Safety Study of Trastuzumab, Paclitaxel and Carboplatin on HER2+ Preoperative Breast Cancer | NCT01170143 | Breast Cancer | Trastuzumab QW,... | 18 Years - 70 Years | Fudan University | |
| Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET) | NCT05063786 | Advanced Breast... | Trastuzumab Alpelisib Fulvestrant Vinorelbine Capecitabine Eribulin | 18 Years - | Spanish Breast Cancer Research Group | |
| NOSTRA-Feasibility Study: A Study Looking at Ultrasound Guided Biopsies for Breast Cancer | NCT04118192 | Breast Cancer | Tumour bed core... | 18 Years - | University of Birmingham | |
| RWD Study in HER2+ mBC Patients in Third-Line Therapy | NCT04566458 | Breast Cancer S... | No intervention | 18 Years - | Exactis Innovation | |
| TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer | NCT06251544 | Breast Cancer Tumor, Breast Breast Tumor Malignant Neopl... Mammary Cancer Mammary Neoplas... Mammary Neoplas... Neoplasm, Breas... | HTR2 T Cells HTR2 T Cells | 18 Years - 80 Years | Baylor College of Medicine | |
| Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | NCT04464967 | Advanced Solid ... Metastatic Canc... HER2-positive B... HER2-positive G... HER-2 Protein O... Esophageal Canc... Ovarian Cancer Endometrium Can... Bladder Cancer Pancreatic Canc... Colorectal Canc... Non Small Cell ... EGF-R Positive ... Head and Neck S... Triple Negative... Cervical Cancer Sarcoma | SNK01 Trastuzumab Cetuximab | 18 Years - 75 Years | NKGen Biotech, Inc. | |
| A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients | NCT03013504 | HER2 Positive B... | HD201 Herceptin Docetaxel Epirubicin Cyclophosphamid... | 18 Years - | Prestige Biopharma Limited | |
| A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors. | NCT04209465 | Solid Tumor | BDTX-189 | 18 Years - | Black Diamond Therapeutics, Inc. | |
| Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET) | NCT05063786 | Advanced Breast... | Trastuzumab Alpelisib Fulvestrant Vinorelbine Capecitabine Eribulin | 18 Years - | Spanish Breast Cancer Research Group | |
| A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04) | NCT02187744 | Early Breast Ca... | PF-05280014 Taxotere® Paraplatin® Trastuzumab-EU Taxotere® Paraplatin® | 18 Years - | Pfizer | |
| Monalizumab and Trastuzumab In Metastatic HER2-pOSitive breAst Cancer: MIMOSA-trial | NCT04307329 | Breast Cancer | Monalizumab Trastuzumab | 18 Years - | The Netherlands Cancer Institute | |
| Efficacy and Safety Study of Trastuzumab, Paclitaxel and Carboplatin on HER2+ Preoperative Breast Cancer | NCT01170143 | Breast Cancer | Trastuzumab QW,... | 18 Years - 70 Years | Fudan University | |
| Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer | NCT03368729 | Metastatic Brea... HER2 Positive B... | Niraparib Trastuzumab | 18 Years - | University of Alabama at Birmingham | |
| Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study | NCT06162559 | Breast Cancer | Tucatinib Trastuzumab Pertuzumab | 18 Years - | The Netherlands Cancer Institute | |
| A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer | NCT03429101 | Breast Cancer | Poziotinib T-DM1 | 18 Years - 90 Years | Spectrum Pharmaceuticals, Inc | |
| EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer | NCT00338247 | Neoplasms, Brea... | lapatinib + cap... | 18 Years - | Novartis | |
| Evaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic Therapy | NCT04928261 | Breast Cancer | Trastuzumab | 18 Years - | Ottawa Hospital Research Institute | |
| Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors | NCT05511844 | HER2-positive B... HER-2 Protein O... HER-2 Gene Ampl... HER2 Gene Mutat... | ORM-5029 | 18 Years - | Orum Therapeutics USA, Inc. | |
| Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors | NCT02500199 | Breast Cancer Gastric Cancer Solid Tumors NSCLC | Pyrotinib | 18 Years - | Hengrui Therapeutics, Inc. | |
| Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer | NCT00820222 | Metastases, Bra... | capecitabine lapatinib trastuzumab | 18 Years - | Novartis | |
| Study of Neoadjuvant Myocet®, Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer | NCT01669239 | Breast Cancer | Liposomal Doxor... | 18 Years - 74 Years | SOLTI Breast Cancer Research Group | |
| A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer (MBC) Whose Disease Has Progressed on or After Trastuzumab | NCT00567879 | Breast Cancer | Panobinostat Trastuzumab | 18 Years - | Novartis | |
| A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach | NCT01774851 | HER-2 Gene Ampl... Esophagus Cance... Gastroesophagea... Stomach Cancer | MM-111 Paclitaxel Trastuzumab | 18 Years - | Merrimack Pharmaceuticals | |
| Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | NCT04464967 | Advanced Solid ... Metastatic Canc... HER2-positive B... HER2-positive G... HER-2 Protein O... Esophageal Canc... Ovarian Cancer Endometrium Can... Bladder Cancer Pancreatic Canc... Colorectal Canc... Non Small Cell ... EGF-R Positive ... Head and Neck S... Triple Negative... Cervical Cancer Sarcoma | SNK01 Trastuzumab Cetuximab | 18 Years - 75 Years | NKGen Biotech, Inc. | |
| Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry | NCT02670577 | Breast Cancer | 18 Years - | Agendia | ||
| Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study | NCT06162559 | Breast Cancer | Tucatinib Trastuzumab Pertuzumab | 18 Years - | The Netherlands Cancer Institute | |
| TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer | NCT06251544 | Breast Cancer Tumor, Breast Breast Tumor Malignant Neopl... Mammary Cancer Mammary Neoplas... Mammary Neoplas... Neoplasm, Breas... | HTR2 T Cells HTR2 T Cells | 18 Years - 80 Years | Baylor College of Medicine | |
| Bevacizumab in Combination With Vinorelbine and Trastuzumab for HER2-Positive, Metastatic Breast Cancer | NCT00670982 | Breast Cancer | bevacizumab vinorelbine trastuzumab | 18 Years - | Dana-Farber Cancer Institute | |
| A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer | NCT03429101 | Breast Cancer | Poziotinib T-DM1 | 18 Years - 90 Years | Spectrum Pharmaceuticals, Inc | |
| Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer | NCT02598427 | HER2 Positive U... Asymptomatic or... | Pertuzumab Trastuzumab | 18 Years - | Duke University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
